Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015

Conference Call and Webcast Today at 4:30 p.m. ET
Royalty revenue for paritaprevir containing regimens was $17.9 million
$30 million milestone payment received from AbbVie for reimbursement approval in Japan for VIEKIRAX®
Cash and marketable securities totaled $236.6 million at December 31, 2015

WATERTOWN, Mass.-- Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first quarter ended December 31, 2015.

Enanta’s cash, cash equivalents and short-term and long-term marketable securities totaled $236.6 million at December 31, 2015. This compares to a total of $209.4 million in such accounts at September 30, 2015. Enanta expects that its current cash, cash equivalents and marketable securities will be sufficient to meet the anticipated cash requirements of its existing business for the foreseeable future.

Published: 09 February 2016

Written by Editor

Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis

100% of Patients receiving multi-target therapy with voclosporin achieved at least a 25% reduction of proteinuria at 8 weeks with a mean decrease of 72%

VICTORIA, British Columbia-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) announced today that it has completed a preliminary analysis of its AURION (Aurinia early Urinary protein Reduction Predicts Response) study. In the first seven patients that have reached at least eight weeks of therapy in the AURION study, 100% (7/7) have achieved at least a 25% reduction in proteinuria compared to study entry. A 25% reduction in proteinuria has been shown to be predictive of a positive clinical response at 24weeks¹. All of the other pre-specified eight week biomarkers of active lupus nephritis (LN) have also improved and are trending towards normalization. These biomarkers have also been shown to be predictive of a positive clinical response at 24 weeks¹.

Published: 08 February 2016

Written by Editor

TSX Nasdaq Up on News Project Update

U.S. Food and Drug Administration (FDA) Grants Breakthrough Therapy Designation to Immunomedics for Sacituzumab Govitecan for the Treatment of Patients With Triple-Negative Breast Cancer

MORRIS PLAINS, N.J., Feb. 05, 2016 -- Immunomedics, Inc., (IMMU) today announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who have failed at least 2 prior therapies for metastatic disease.

The Breakthrough Therapy Designation was supported by a Phase 2 study in patients with metastatic TNBC who had received a median of 5 prior therapies (range, 2 – 12).

Published: 05 February 2016

Written by Editor

Nasdaq FDA HC Decision Up on News

FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis

Focusing on Initial Registration in NASH Cirrhosis With Parallel Development in NASH Fibrosis

SAN DIEGO, Feb. 03, 2016 -- Conatus Pharmaceuticals Inc. (CNAT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s emricasan development program for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis (NASH). Based on additional communications with the FDA recommending single-etiology clinical trials, the company plans to focus on advancing toward initial registration of emricasan for patients with NASH cirrhosis, with parallel development toward registration of emricasan for patients with NASH fibrosis, and supportive clinical trials addressing additional patient populations.

Published: 03 February 2016

Written by Editor

Nasdaq FDA HC Decision Up on News

Sinovac Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company and Formation of Independent Special Committee

BEIJING, Feb. 1, 2016 -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the "Board") has received a preliminary non-binding proposal letter, dated January 30, 2016, from Mr. Weidong Yin, chairman, president and chief executive officer of the Company, SAIF Partners IV L.P. and/or its affiliates, to acquire all of the outstanding common shares of the Company not owned by them or their affiliates for $6.18 in cash per common share. A copy of the proposal letter is attached hereto as Exhibit A.

The Board has formed a special committee consisting of three independent directors (the "Special Committee"), Mr. Simon Anderson, Mr. Yuk Lam Lo and Mr. Meng Mei, to consider the proposal. Mr. Simon Anderson is appointed as the chairman of the Special Committee. The Company expects that the Special Committee will retain independent advisors, including independent financial and legal advisors, to assist it in this process.

Published: 01 February 2016

Written by Editor

Nasdaq M & A Up on News

Enanta Pharmaceuticals Inc ( ENTA )

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015

Aurinia Pharmaceuticals Inc ( AUP / AUPH )

Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis

Immunomedics Inc ( IMMU )

U.S. Food and Drug Administration (FDA) Grants Breakthrough Therapy Designation to Immunomedics for Sacituzumab Govitecan for the Treatment of Patients With Triple-Negative Breast Cancer

Conatus Pharmaceuticals Inc ( CNAT )

FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis

Sinovac Biotech Ltd ( SVA )

Sinovac Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company and Formation of Independent Special Committee